Genetics and biomarkers in personalisation of lung cancer treatment

The Lancet

Volumn 382, Issue 9893, 2013, Pages 720-731

  Rosell, Rafael ^a,b,c   Bivona, Trever G ^c,d   Karachaliou, Niki ^b,c,e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Unit for Cancer Research   (Spain)

^c Cancer Therapeutics Innovation Group   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BEVACIZUMAB; BH3 PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR; DOCETAXEL; DROZITUMAB; DULANERMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; K RAS PROTEIN; NAVITOCLAX; PACLITAXEL; PROCASPASE 8; SELUMETINIB; TRAMETINIB; TRANSCRIPTION FACTOR FKHRL1; TRICIRIBINE; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER REGRESSION; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CYTOPLASM; DNA DAMAGE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MONOTHERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 84882977045     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61715-8     Document Type: Review

References (96)

1. P Goldstraw, D Ball, JR Jett et al. Non-small-cell lung cancer Lancet 378 2011 1727 1740
2. B Vogelstein, N Papadopoulos, VE Velculescu, S Zhou, LA Diaz Jr, KW Kinzler Cancer genome landscapes Science 339 2013 1546 1558
3. R Rosell, T Moran, C Queralt et al. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
4. R Rosell, E Carcereny, R Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
5. R Bernards A missing link in genotype-directed cancer therapy Cell 151 2012 465 468
6. EL Kwak, YJ Bang, DR Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
7. W Pao, N Girard New driver mutations in non-small-cell lung cancer Lancet Oncol 12 2011 175 180
8. RS Heist, JA Engelman SnapShot: non-small cell lung cancer Cancer Cell 21 2012 448.e2
9. CM Blakely, TG Bivona Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance Cancer Discov 2 2012 872 875
10. R Buettner, J Wolf, RK Thomas Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment J Clin Oncol 31 2013 1858 1865
11. JY Yang, CJ Chang, W Xia et al. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer Cancer Res 70 2010 4709 4718
12. JS Seo, YS Ju, WC Lee et al. The transcriptional landscape and mutational profile of lung adenocarcinoma Genome Res 22 2012 2109 2119
13. T Zander, L Heukamp, M Bos et al. Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment J Clin Oncol 30 suppl 2012 abstr CRA10529.
14. ML Sos, RK Thomas Genetic insight and therapeutic targets in squamous-cell lung cancer Oncogene 31 2012 4811 4814
15. A Drilon, N Rekhtman, M Ladanyi, P Paik Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy Lancet Oncol 13 2012 e418 e426
16. MH Cullen, R Joshi, AD Chetiyawardana, CM Woodroffe Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare Br J Cancer 58 1988 359 361
17. JH Schiller, D Harrington, CP Belani et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
18. D Jablonski Lessons from the past: evolutionary impacts of mass extinctions Proc Natl Acad Sci USA 98 2001 5393 5398
19. GV Hegde, CC de la Cruz, C Chiu et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer Sci Transl Med 5 2013 171ra18
20. R Rosell Lung adenocarcinoma R Rosell Molecular-based decision making for personalized cancer management 2012 Future Medicine London 137 165
21. JE Allen, G Krigsfeld, PA Mayes et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects Sci Transl Med 5 2013 171ra17
22. LY Dimberg, CK Anderson, R Camidge, K Behbakht, A Thorburn, HL Ford On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics Oncogene 32 2013 1341 1350
23. R Rosell, MA Molina, MJ Serrano EGFR mutations in circulating tumour DNA Lancet Oncol 13 2012 971 973
24. KW Wagner, EA Punnoose, T Januario et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Nat Med 13 2007 1070 1077
25. HM Stern, M Padilla, K Wagner, L Amler, A Ashkenazi Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab Clin Cancer Res 16 2010 1587 1596
26. M Incoronato, M Garofalo, L Urso et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED Cancer Res 70 2010 3638 3646
27. G Romano, M Acunzo, M Garofalo et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation Proc Natl Acad Sci USA 109 2012 16570 16575
28. F Fiory, P Formisano, G Perruolo, F Beguinot Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism Am J Physiol Endocrinol Metab 297 2009 E592 E601
29. J Kuroda, H Puthalakath, MS Cragg et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic Proc Natl Acad Sci USA 103 2006 14907 14912
30. MS Cragg, J Kuroda, H Puthalakath, DC Huang, A Strasser Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med 4 2007 1681 1689
31. Y Gong, R Somwar, K Politi et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas PLoS Med 4 2007 e294
32. DB Costa, B Halmos, A Kumar et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations PLoS Med 4 2007 1669 1679
33. AI Nieminen, VM Eskelinen, HM Haikala et al. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis Proc Natl Acad Sci USA 110 2013 E1839 E1848
34. T Akiyama, CR Dass, PF Choong Bim-targeted cancer therapy: a link between drug action and underlying molecular changes Mol Cancer Ther 8 2009 3173 3180
35. AC Faber, RB Corcoran, E Hiromichi et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors Cancer Discov 1 2011 352 365
36. LE Littlepage, AS Adler, H Kouros-Mehr et al. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression Cancer Discov 2 2012 638 651
37. PA Janne, AT Shaw, JR Pereira et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 2013 38 47
38. Z Chen, K Cheng, Z Walton et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 483 2012 613 617
39. DB Shackelford, E Abt, L Gerken et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin Cancer Cell 23 2013 143 158
40. M Molina-Arcas, DC Hancock, C Sheridan, MS Kumar, J Downward Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer Cancer Discov 3 2013 548 563
41. JA Engelman, L Chen, X Tan et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
42. J Konishi, F Yi, X Chen, H Vo, DP Carbone, TP Dang Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim Oncogene 29 2010 589 596
43. A Maraver, PJ Fernandez-Marcos, D Herranz et al. Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK Cancer Cell 22 2012 222 234
44. B Westhoff, IN Colaluca, G D'Ario et al. Alterations of the Notch pathway in lung cancer Proc Natl Acad Sci USA 106 2009 22293 22298
45. RB Corcoran, KA Cheng, AN Hata et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23 2013 121 128
46. S Malik, RG Roeder The metazoan mediator co-activator complex as an integrative hub for transcriptional regulation Nat Rev Genet 11 2010 761 772
47. X Yang, M Zhao, M Xia et al. Selective requirement for Mediator MED23 in Ras-active lung cancer Proc Natl Acad Sci USA 109 2012 E2813 E2822
48. L He, K Torres-Lockhart, N Forster et al. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma Cancer Discov 3 2013 324 337
49. S Xargay-Torrent, M Lopez-Guerra, I Saborit-Villarroya et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters Clin Cancer Res 17 2011 3956 3968
50. IE Wertz, S Kusam, C Lam et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 Nature 471 2011 110 114
51. L Reavie, SM Buckley, E Loizou et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression Cancer Cell 23 2013 362 375
52. LH Schmidt, T Spieker, S Koschmieder et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth J Thorac Oncol 6 2011 1984 1992
53. T Gutschner, S Diederichs The hallmarks of cancer: a long non-coding RNA point of view RNA Biol 9 2012 703 719
54. LV Sequist, BA Waltman, D Dias-Santagata et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 2011 75ra26
55. K Tabara, R Kanda, K Sonoda et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells PLoS One 7 2012 e41017
56. Z Zhang, JC Lee, L Lin et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat Genet 44 2012 852 860
57. D Mahadevan, L Cooke, C Riley et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors Oncogene 26 2007 3909 3919
58. R Rosell Triple-negative breast cancer R Rosell Molecular-based decision making for personalized cancer management 2012 Future Medicine London 75
59. S Ammoun, L Provenzano, L Zhou et al. Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival Oncogene 2013 10.1038/onc.2012.587 published online Jan 14.
60. TG Bivona, H Hieronymus, J Parker et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR Nature 471 2011 523 526
61. JD Paccez, GJ Vasques, RG Correa et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target Oncogene 32 2013 689 698
62. SP Gao, KG Mark, K Leslie et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas J Clin Invest 117 2007 3846 3856
63. K Rikova, A Guo, Q Zeng et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
64. JM Stommel, AC Kimmelman, H Ying et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 2007 287 290
65. LA Byers, L Diao, J Wang et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance Clin Cancer Res 19 2013 279 290
66. GN Naumov, MB Nilsson, T Cascone et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance Clin Cancer Res 15 2009 3484 3494
67. M Lu, H Breyssens, V Salter et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP Cancer Cell 23 2013 618 633
68. S Huang, M Holzel, T Knijnenburg et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling Cell 151 2012 937 950
69. M Serizawa, T Takahashi, N Yamamoto, Y Koh Combined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells J Thorac Oncol 8 2013 259 269
70. SX Atwood, M Li, A Lee, JY Tang, AE Oro GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas Nature 494 2013 484 488
71. Y Wang, Q Ding, CJ Yen et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways Cancer Cell 21 2012 374 387
72. SS Pullamsetti, GA Banat, A Schmall et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF Oncogene 32 2013 1121 1134
73. J Massague TGFbeta signalling in context Nat Rev Mol Cell Biol 13 2012 616 630
74. R Rosell Mediator subunit MED12 - a predictor of emergent resistance in oncogene-driven cancers N Engl J Med 368 2013 1551 1552
75. S Misale, R Yaeger, S Hobor et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
76. W Pao, VA Miller, KA Politi et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
77. S Kobayashi, TJ Boggon, T Dayaram et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
78. ME Arcila, GR Oxnard, K Nafa et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Clin Cancer Res 17 2011 1169 1180
79. R Rosell, MA Molina, C Costa et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-teated advanced non-small-cell lung cancer patients with EGFR mutations Clin Cancer Res 17 2011 1160 1168
80. KY Su, HY Chen, KC Li et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J Clin Oncol 30 2012 433 440
81. S Maheswaran, LV Sequist, S Nagrath et al. Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 2008 366 377
82. Y Fujita, K Suda, H Kimura et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation J Thorac Oncol 7 2012 1640 1644
83. Rosell R, Massuti B, Costa C, et al. Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (v3). ESMO Conference; Vienna, Austria; Sept 28-Oct 2, 2012. Abstract 929.
84. J Tanizaki, I Okamoto, S Fumita, W Okamoto, K Nishio, K Nakagawa Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification Oncogene 30 2011 4097 4106
85. J Wu, P Dent, T Jelinek, A Wolfman, MJ Weber, TW Sturgill Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′- monophosphate Science 262 1993 1065 1069
86. SJ Cook, F McCormick Inhibition by cAMP of Ras-dependent activation of Raf Science 262 1993 1069 1072
87. BJ Lipworth Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease Lancet 365 2005 167 175
88. H Schnidar, M Eberl, S Klingler et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway Cancer Res 69 2009 1284 1292
89. M Eberl, S Klingler, D Mangelberger et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells EMBO Mol Med 4 2012 218 233
90. AS Little, PD Smith, SJ Cook Mechanisms of acquired resistance to ERK1/2 pathway inhibitors Oncogene 32 2013 1207 1215
91. JS Duncan, MC Whittle, K Nakamura et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer Cell 149 2012 307 321
92. P Lito, CA Pratilas, EW Joseph et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Cancer Cell 22 2012 668 682
93. JM Spoerke, C O'Brien, L Huw et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models Clin Cancer Res 18 2012 6771 6783
94. LA Garraway, ES Lander Lessons from the cancer genome Cell 153 2013 17 37
95. T Bivona, P Giannikopoulos, C Costa et al. Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients J Clin Oncol 31 suppl 2013 abstr 11067.
96. YW Lam Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice ISRN Pharmacol 2013 2013 641089